CXCR4 and cancer: Thus, targeting the CXCL12/CXCR4/CXCR7 has recently been explored for the treatment of cancer with the development of multiple CXCR12 (30D8) and CXCR4 (MD3100, MSX-122, BPRCX807, WZ811, motixafortide, TN14003, AMD3465, and AMD1170, MDX1338/ulocuplumab) antagonist alternatives that are currently being explored in preclinical and clinical studies [219].